A randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis

The Phase 3 primary publication. The primary endpoint was not met; a pre-specified analysis of participants with baseline ALSFRS-R ≥ 35 showed a clinical response at 28 weeks.